{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:58:28Z","timestamp":1791316708785,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No.82573471"],"award-info":[{"award-number":["Grant No.82573471"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["Grant No.23JCZDJC00200"],"award-info":[{"award-number":["Grant No.23JCZDJC00200"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tianjin Key Medical Discipline Construction Project","award":["Grant No.TJYXZDXK-3-003A"],"award-info":[{"award-number":["Grant No.TJYXZDXK-3-003A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small cell lung cancer (SCLC) remains a highly lethal malignancy with limited therapeutic options. The purpose of this study was to investigate the central role of histone deacetylase 6 (HDAC6) in SCLC progression and its regulatory mechanisms to identify novel therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Preclinical SCLC models were utilized alongside molecular, cellular, and immunological techniques to elucidate HDAC6's mechanistic functions. The deacetylation of S100A2 and its impact on downstream signaling were analyzed, compensatory responses to HDAC6 inhibition were assessed, and the efficacy of dual-target inhibition was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HDAC6 was found to deacetylate the calcium-binding protein S100A2 at lysine 27, thereby stabilizing TGF-\u03b2\/SMAD signaling to promote epithelial-mesenchymal transition (EMT) and metastatic dissemination. Simultaneously, HDAC6 polarized macrophages toward tumor-promoting M2 phenotypes, fostering an immunosuppressive microenvironment. HDAC6 inhibition triggered compensatory CSF1R upregulation, revealing a resistance mechanism. Dual blockade of HDAC6 and CSF1R synergistically suppressed primary tumor growth and metastasis while reprogramming macrophages toward anti-tumor M1 states. SCLC patients with co-high expression of HDAC6 and CSF1R exhibited worse progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study defines the HDAC6-S100A2-TGF-\u03b2\/SMAD and HDAC6-CSF1R-macrophage axes as actionable therapeutic vulnerabilities. The dual inhibition strategy provides a translational framework to overcome stromal and immune barriers in this recalcitrant cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02552-y","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:08:30Z","timestamp":1767780510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-\u03b2\/SMAD and CSF1R signaling"],"prefix":"10.1186","volume":"25","author":[{"given":"Yantao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2552_CR1","doi-asserted-by":"publisher","unstructured":"Sen T. et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024; 21: 610\u2013627. https:\/\/doi.org\/10.1038\/s41571-024-00914-x.","DOI":"10.1038\/s41571-024-00914-x"},{"key":"2552_CR2","doi-asserted-by":"publisher","unstructured":"Kim SY, Park HS & Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025; 333: 1906\u20131917. https:\/\/doi.org\/10.1001\/jama.2025.0560","DOI":"10.1001\/jama.2025.0560"},{"key":"2552_CR3","doi-asserted-by":"publisher","unstructured":"Lee JH, Saxena A & Giaccone G. Advancements in small cell lung cancer. Semin Cancer Biol. 2023; 93: 123\u2013128. https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.008.","DOI":"10.1016\/j.semcancer.2023.05.008"},{"key":"2552_CR4","doi-asserted-by":"publisher","unstructured":"Dolkar T, Gates C, Hao Z & Munker R. New developments in immunotherapy for SCLC. J Immun Cancer. 2025; 13. https:\/\/doi.org\/10.1136\/jitc-2024-009667.","DOI":"10.1136\/jitc-2024-009667"},{"key":"2552_CR5","doi-asserted-by":"publisher","unstructured":"Megyesfalvi Z. et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clinic. 2023; 73: 620\u2013652. https:\/\/doi.org\/10.3322\/caac.21785.","DOI":"10.3322\/caac.21785"},{"key":"2552_CR6","doi-asserted-by":"publisher","unstructured":"Liu Y. et al. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. Cancer Res. 2018; 78: 3709\u20133717. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0161.","DOI":"10.1158\/0008-5472.Can-18-0161"},{"key":"2552_CR7","doi-asserted-by":"publisher","unstructured":"Qin T. et al. Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer. Adv Sci (Weinh). 2025; 12: e2413445. https:\/\/doi.org\/10.1002\/advs.202413445.","DOI":"10.1002\/advs.202413445"},{"key":"2552_CR8","doi-asserted-by":"publisher","unstructured":"Petty WJ & Paz-Ares L. Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review. JAMA Oncol. 2023; 9: 419\u2013429. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5631.","DOI":"10.1001\/jamaoncol.2022.5631"},{"key":"2552_CR9","doi-asserted-by":"publisher","unstructured":"Zugazagoitia J & Paz-Ares L. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022; 40: 671\u2013680. https:\/\/doi.org\/10.1200\/jco.21.01881.","DOI":"10.1200\/jco.21.01881"},{"key":"2552_CR10","doi-asserted-by":"publisher","unstructured":"Chan JM. et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021; 39: 1479\u20131496.e1418 (2021). https:\/\/doi.org\/10.1016\/j.ccell.2021.09.008.","DOI":"10.1016\/j.ccell.2021.09.008"},{"key":"2552_CR11","doi-asserted-by":"publisher","unstructured":"Swain SM, Shastry M & Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023; 22: 101\u2013126. https:\/\/doi.org\/10.1038\/s41573-022-00579-0.","DOI":"10.1038\/s41573-022-00579-0"},{"key":"2552_CR12","doi-asserted-by":"publisher","unstructured":"Jiang Y. et al. HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype. NPJ Precis Oncol. 2025; 9: 150. https:\/\/doi.org\/10.1038\/s41698-025-00949-y.","DOI":"10.1038\/s41698-025-00949-y"},{"key":"2552_CR13","doi-asserted-by":"publisher","unstructured":"Ducellier S. et al. Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells. J Immun Cancer. 2024; 12. https:\/\/doi.org\/10.1136\/jitc-2023-007588.","DOI":"10.1136\/jitc-2023-007588"},{"key":"2552_CR14","doi-asserted-by":"publisher","unstructured":"Jha S. et al. Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue. Eur J Med Chem. 2024; 265: 116057. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116057.","DOI":"10.1016\/j.ejmech.2023.116057"},{"key":"2552_CR15","doi-asserted-by":"publisher","unstructured":"Kaur S, Rajoria P & Chopra M. HDAC6: A unique HDAC family member as a cancer target. Cellular oncology (Dordrecht, Netherlands). 2022; 45; 779\u2013829. https:\/\/doi.org\/10.1007\/s13402-022-00704-6.","DOI":"10.1007\/s13402-022-00704-6"},{"key":"2552_CR16","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/0008-5472.CAN-20-2808","volume":"81","author":"M Zhu","year":"2021","unstructured":"Zhu M, et al. Evasion of innate immunity contributes to small cell lung cancer progression and metastasis. Cancer Res. 2021;81:1813\u201326.","journal-title":"Cancer Res"},{"key":"2552_CR17","doi-asserted-by":"publisher","unstructured":"Kovalovsky D. et al. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy. Sci Adv. 2024; 10: eadp3687. https:\/\/doi.org\/10.1126\/sciadv.adp3687.","DOI":"10.1126\/sciadv.adp3687"},{"key":"2552_CR18","doi-asserted-by":"publisher","unstructured":"Horwitz SM. et al. Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial. Nature Med. 2024; 30: 2517\u20132527. https:\/\/doi.org\/10.1038\/s41591-024-03076-6.","DOI":"10.1038\/s41591-024-03076-6"},{"key":"2552_CR19","doi-asserted-by":"publisher","unstructured":"Deng Y. et al. HDAC6-dependent deacetylation of AKAP12 dictates its ubiquitination and promotes colon cancer metastasis. Cancer Lett. 2022; 549: 215911. https:\/\/doi.org\/10.1016\/j.canlet.2022.215911.","DOI":"10.1016\/j.canlet.2022.215911"},{"key":"2552_CR20","doi-asserted-by":"publisher","unstructured":"Deskin B. et al. Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer. Transl Oncol. 2020; 13: 135\u2013145. https:\/\/doi.org\/10.1016\/j.tranon.2019.11.001.","DOI":"10.1016\/j.tranon.2019.11.001"},{"key":"2552_CR21","doi-asserted-by":"publisher","unstructured":"Li C. et al. The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer. Human Pathol. 2018; 75: 16\u201325. https:\/\/doi.org\/10.1016\/j.humpath.2017.11.010.","DOI":"10.1016\/j.humpath.2017.11.010"},{"key":"2552_CR22","doi-asserted-by":"publisher","unstructured":"Zhang Z, Cao Y, Zhao W, Guo L & Liu W. HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma. Cancer Biomark. 2017; 19: 169\u2013175. https:\/\/doi.org\/10.3233\/cbm-160298.","DOI":"10.3233\/cbm-160298"},{"key":"2552_CR23","doi-asserted-by":"publisher","unstructured":"George J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524: 47\u201353. https:\/\/doi.org\/10.1038\/nature14664.","DOI":"10.1038\/nature14664"},{"key":"2552_CR24","doi-asserted-by":"publisher","unstructured":"Liu W, Jiang Y, Li G, Huang D & Qin T. Oxidative phosphorylation related gene COA6 is a novel indicator for the prognosis and immune response in lung adenocarcinoma. Sci. Rep. 2024; 14: 25970. https:\/\/doi.org\/10.1038\/s41598-024-77775-y.","DOI":"10.1038\/s41598-024-77775-y"},{"key":"2552_CR25","doi-asserted-by":"publisher","unstructured":"Wang J. et al. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Lett. 2021; 503: 197\u2013212. https:\/\/doi.org\/10.1016\/j.canlet.2021.01.008.","DOI":"10.1016\/j.canlet.2021.01.008"},{"key":"2552_CR26","doi-asserted-by":"publisher","unstructured":"Chen Q. et al. S100A2 induces epithelial-mesenchymal transition and metastasis in pancreatic cancer by coordinating transforming growth factor \u03b2 signaling in SMAD4-dependent manner. Cell Death Discov. 2023; 9: 356. https:\/\/doi.org\/10.1038\/s41420-023-01661-1.","DOI":"10.1038\/s41420-023-01661-1"},{"key":"2552_CR27","doi-asserted-by":"publisher","unstructured":"Yu J. et al. Diterpene glycosides from Fructus Rubi ameliorates benign prostatic hyperplasia in rats through the androgen and TGF-\u03b2\/Smad signaling pathway. J Ethnopharmacol. 2025; 337: 118756 (2025). https:\/\/doi.org\/10.1016\/j.jep.2024.118756.","DOI":"10.1016\/j.jep.2024.118756"},{"key":"2552_CR28","doi-asserted-by":"publisher","unstructured":"Pulya S. et al. HDAC6 as privileged target in drug discovery: A perspective. Pharmacol Res. 2021; 163: 105274. https:\/\/doi.org\/10.1016\/j.phrs.2020.105274.","DOI":"10.1016\/j.phrs.2020.105274"},{"key":"2552_CR29","doi-asserted-by":"publisher","unstructured":"Liu P. et al. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90. Mol Med. 2021; 27; 110. https:\/\/doi.org\/10.1186\/s10020-021-00375-3.","DOI":"10.1186\/s10020-021-00375-3"},{"key":"2552_CR30","doi-asserted-by":"publisher","unstructured":"Mangaonkar S, Nath S & Chatterji BP. Microtubule dynamics in cancer metastasis: Harnessing the underappreciated potential for therapeutic interventions. Pharmacol Ther. 2024; 263: 108726. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108726.","DOI":"10.1016\/j.pharmthera.2024.108726"},{"key":"2552_CR31","doi-asserted-by":"publisher","unstructured":"Biersack B, Nitzsche B & H\u00f6pfner M. Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization. Semin Cell Dev Biol. 2024; 154: 286\u2013294. https:\/\/doi.org\/10.1016\/j.semcdb.2022.09.009.","DOI":"10.1016\/j.semcdb.2022.09.009"},{"key":"2552_CR32","doi-asserted-by":"publisher","unstructured":"Bulk E. et al. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res. 2009; 15: 22\u201329. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-0953.","DOI":"10.1158\/1078-0432.Ccr-08-0953"},{"key":"2552_CR33","doi-asserted-by":"publisher","unstructured":"Li C. et al. S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer. Faseb J. 2020; 34: 13333\u201313344. https:\/\/doi.org\/10.1096\/fj.202000555R.","DOI":"10.1096\/fj.202000555R"},{"key":"2552_CR34","doi-asserted-by":"publisher","unstructured":"Han F. et al. The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis. Oncogene. 2020; 41: 657\u2013670. :https:\/\/doi.org\/10.1038\/s41388-021-02116-6.","DOI":"10.1038\/s41388-021-02116-6"},{"key":"2552_CR35","doi-asserted-by":"publisher","unstructured":"Deng M. et al. S100A2 promotes clear cell renal cell carcinoma tumor metastasis through regulating GLUT2 expression. Cell Death Dis. 2025; 16: 135. https:\/\/doi.org\/10.1038\/s41419-025-07418-1.","DOI":"10.1038\/s41419-025-07418-1"},{"key":"2552_CR36","doi-asserted-by":"publisher","unstructured":"Sobolewski C. et al. S100A11\/ANXA2 belongs to a tumour suppressor\/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Gut. 2020; 69: 1841\u20131854. https:\/\/doi.org\/10.1136\/gutjnl-2019-319019.","DOI":"10.1136\/gutjnl-2019-319019"},{"key":"2552_CR37","doi-asserted-by":"publisher","unstructured":"Dowling CM. et al. Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Sci Adv. 2021; 7. :https:\/\/doi.org\/10.1126\/sciadv.abc4897.","DOI":"10.1126\/sciadv.abc4897"},{"key":"2552_CR38","doi-asserted-by":"publisher","unstructured":"Zamperla MG. et al. HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape. Clin Epigenetics. 2024; 16: 109. :https:\/\/doi.org\/10.1186\/s13148-024-01725-8.","DOI":"10.1186\/s13148-024-01725-8"},{"key":"2552_CR39","doi-asserted-by":"publisher","unstructured":"Peng J, Ma Y, Zhao X, Yang X & Wang H. Constitutive \u03b2-Catenin Overexpression Represses Lncrna MIR100HG Transcription via HDAC6-Mediated Histone Modification in Colorectal Cancer. Mol Cancer Res. 2022; 20: 949\u2013959. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-21-0923.","DOI":"10.1158\/1541-7786.Mcr-21-0923"},{"key":"2552_CR40","doi-asserted-by":"publisher","unstructured":"Stahl D. et al. CSF1R(+) myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer Cell. 2025. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.013.","DOI":"10.1016\/j.ccell.2025.05.013"},{"key":"2552_CR41","doi-asserted-by":"publisher","unstructured":"Gelderblom H. et al. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib. Clin Cancer Res. 2024; 30: 3996\u20134004. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0103.","DOI":"10.1158\/1078-0432.Ccr-24-0103"},{"key":"2552_CR42","doi-asserted-by":"publisher","unstructured":"Wen J, Wang S, Guo R & Liu D. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. Eur J Med Chem. 2023; 245: 114884. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114884.","DOI":"10.1016\/j.ejmech.2022.114884"},{"key":"2552_CR43","doi-asserted-by":"publisher","unstructured":"Hoxhaj G & Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nature reviews. Cancer. 2020; 20: 74\u201388. https:\/\/doi.org\/10.1038\/s41568-019-0216-7.","DOI":"10.1038\/s41568-019-0216-7"},{"key":"2552_CR44","doi-asserted-by":"publisher","unstructured":"Zhan T, Rindtorff N & Boutros M. Wnt signaling in cancer. Oncogene. 2017; 36: 1461\u20131473. https:\/\/doi.org\/10.1038\/onc.2016.304.","DOI":"10.1038\/onc.2016.304"},{"key":"2552_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023;8:69.","journal-title":"Signal Transduct Target Ther"},{"key":"2552_CR46","doi-asserted-by":"publisher","unstructured":"Zhou H. et al. The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review. Transl Lung Cancer Res. 2024; 13: 3778\u20133794. https:\/\/doi.org\/10.21037\/tlcr-24-964.","DOI":"10.21037\/tlcr-24-964"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02552-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:14:53Z","timestamp":1781626493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02552-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the ethics committee of the Tianjin Medical University Cancer Institute and Hospital. Animal experiments were approved by the Animal Care and Use Committee of Tianjin Cancer Institute & Hospital of Tianjin Medical University (Approval No. AE-2022004). Informed consent was obtained from all participants, and the study adhered to the principles of the 1975 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained from each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}